Cover Image
市場調查報告書

生物標記的全球市場分析:各類型 (安全性,有效性,驗證),各用途 (診斷,藥物開發,個人化醫療),各疾病 (腫瘤,心臟,神經,免疫),市場區隔預測

Biomarkers Market Analysis By Type (Safety, Efficacy, Validation), By Application (Diagnostics, Drug Development, Personalized Medicine), By Disease (Oncology, Cardiovascular, Neurology, Immunology) And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 368033
出版日期 內容資訊 英文 84 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物標記的全球市場分析:各類型 (安全性,有效性,驗證),各用途 (診斷,藥物開發,個人化醫療),各疾病 (腫瘤,心臟,神經,免疫),市場區隔預測 Biomarkers Market Analysis By Type (Safety, Efficacy, Validation), By Application (Diagnostics, Drug Development, Personalized Medicine), By Disease (Oncology, Cardiovascular, Neurology, Immunology) And Segment Forecasts To 2024
出版日期: 2016年08月02日 內容資訊: 英文 84 Pages
簡介

本報告提供全球生物標記市場相關調查,彙整產業預測,以及各類型,各用途,各疾病,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 摘要整理

第2章 市場概要

第3章 市場變動,教友,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 有利的政府配合措施
  • 簡報,成長預測製圖
  • SWOT分析
  • 波特產業分析

第4章 各類型預測及趨勢分析

  • 各類型趨勢分析
  • 安全性
  • 有效性
  • 驗證

第5章 各用途預測及趨勢分析

  • 各用途趨勢分析
  • 診斷
  • 藥物開發
  • 個人化醫療
  • 其他

第6章 各疾病預測及趨勢分析

  • 各疾病趨勢分析
  • 癌症
  • 心血管
  • 神經
  • 免疫
  • 其他

第7章 各地區預測

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
    • Roche Diagnostics Ltd.
    • Abbott Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Siemens Healthcare GmbH
    • Epigenomics AG
    • GE Healthcare
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Qiagen, Inc.
    • Johnson. Johnson
    • Merck. Co., Inc.

圖表

目錄

The global biomarkers market is expected to reach over USD 78.2 billion by 2024, according to a new report by Grand View Research, Inc. The growing demand for companion diagnostics and the rising adoption of personalized medicine are the key factors propelling the growth of the biomarkers market. The increasing need of disease-specific biomarkers for the development of diagnostics, the increasing R&D funding, and the rising prevalence of oncology and cardiovascular-based diseases are anticipated to create significant opportunities for the market growth during the forecast period.

The spiraling population and the upward trend in the adoption of sedentary lifestyles are expected to provide the industry with a huge target population base. Government grants and research funding for the discovery and development of novel biomarkers are the other factors accentuating the market growth. The introduction of the biomarker-based diagnostic kits for screening high-risk population coupled with the growing prevalence of genetic disorders is also anticipated to increase the client base for this market.

Further key findings from the study suggest:

The safety biomarkers segment held the largest share of over 40% in 2015 owing to the increasing routine healthcare checkups and the growing base of the geriatric population that is at a high risk of developing various diseases

The validation biomarkers segment is determined as one of the fastest growing segments. The increasing R&D initiatives for the development of more specific biomarkers, and hence the subsequent development of companion diagnostics with enhanced accuracy and sensitivity for the effective detection of diseases are key factors contributing towards the aforementioned growth.

The drug discovery segment dominated the application segment in 2015. Biomarkers are extensively used by pharmaceutical companies to accelerate the development of new drug findings and to predict the failure of the upcoming drugs.

The diagnostic segment is estimated to witness a lucrative growth over the forecast period owing to the growing awareness about routine healthcare checkups and the rising prevalence of various diseases

In 2015, the oncology segment dominated with a revenue generated over USD 9.2 billion owing to the introduction of companion diagnostic tests for oncology drugs and the growing burden of cancer across the globe

The cardiovascular segment is expected to be the fastest growing segment with a CAGR of over 14.0%. The growing adoption of sedentary lifestyles and the rise in the obese population base leading to cardiovascular diseases are estimated to provide this market with a potential growth platform.

North America held the largest regional share of around 39% in 2015. The well-established R&D infrastructure and the high level of disposable income are the factors contributing towards the large market share.

Asia Pacific is anticipated to be the fastest growing biomarker market owing to the factors, such as the developing economic conditions, a large base of the target population, and a favorable regulatory scenario for clinical trials.

Major players include Roche Diagnostics Ltd., Abbott Laboratories, Inc., Agilent Technologies, Inc., Epigenomics AG, GE Healthcare, Johnson and Johnson, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, Qiagen, Inc., Merck& Co., Inc., and others

Market participants are ensuring stability by fundingthe growing R&D initiatives and focusing on the developing countries through the expansion and introduction of novel biomarker diagnostics.In 2015, Pfizer, Inc. developed a lung cancer therapy drug, Crizotinib used in non-small cell lung cancer therapy associated with ALK fusions.

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Market Snapshot

Chapter 3: Market Variables, Trends. Scope

  • 3.1. Market segmentation. scope
    • 3.1.1. Market Driver Analysis
    • 3.1.2. Presence of favorable government initiatives
  • 3.2. Penetration. growth prospect mapping
  • 3.3. Biomarker-SWOT Analysis, By Factor(political. legal, economic and technological)
  • 3.4. Industry Analysis-Porter's

Chapter 4: Market Categorization 1: Biomarker Type Estimates. Trend Analysis

  • 4.1. Biomarker market: type movement analysis
  • 4.2. Safety
    • 4.2.1. Safety market, 2013-2024(USD Million)
  • 4.3. Efficacy
    • 4.3.1. Efficacy market, 2013-2024(USD Million)
  • 4.4. Validation
    • 4.4.1. Validation market, 2013-2024(USD Million)

Chapter 5: Market Categorization 2: Biomarker Application Estimates. Trend Analysis

  • 5.1. Biomarker market: application movement analysis
  • 5.2. Diagnostics
    • 5.2.1. Diagnostics market, 2013-2024(USD Million)
  • 5.3. Drug Development
    • 5.3.1. Drug Developmentmarket, 2013-2024(USD Million)
  • 5.4. Personalized Medicine
    • 5.4.1. Personalized Medicinemarket, 2013-2024(USD Million)
  • 5.5. Others
    • 5.5.1. Othersmarket, 2013-2024(USD Million)

Chapter 6: Market Categorization 3: Biomarker Disease Estimates. Trend Analysis

  • 6.1. Biomarker market: disease movement analysis
  • 6.2. Oncology
    • 6.2.1. Oncologymarket, 2013-2024(USD Million)
  • 6.3. Cardiovascular
    • 6.3.1. Cardiovascularmarket, 2013-2024(USD Million)
  • 6.4. Neurology
    • 6.4.1. Neurologymarket, 2013-2024(USD Million)
  • 6.5. Immunology
    • 6.5.1. Immunologymarket, 2013-2024(USD Million)
  • 6.6. Others
    • 6.6.1. Othersmarket, 2013-2024(USD Million)

Chapter 7: Market Categorization 4: Regional Estimates. Trend Analysis by Type, Application, and Disease

  • 7.1. Biomarker market share by region, 2015. 2024
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. UK
    • 7.3.3. France
  • 7.4. Asia Pacific
    • 7.4.1. Japan
    • 7.4.2. India
    • 7.4.3. China
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
  • 7.6. MEA
    • 7.6.1. South Africa

Chapter 8: Competitive Landscape

  • 8.1. Strategy framework
  • 8.2. Market participation categorization
  • 8.3. Company Profiles
    • 8.3.1. Roche Diagnostics Ltd.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Abbott Laboratories, Inc.
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Agilent Technologies, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Siemens Healthcare GmbH
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Epigenomics AG
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. GE Healthcare
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Thermo Fisher Scientific, Inc.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Bio-Rad Laboratories, Inc.
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Qiagen, Inc.
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Johnson. Johnson
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Merck. Co., Inc.
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives

List of Tables

  • TABLE 1: Biomarker Market Driver Analysis
  • TABLE 2: North America Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 3: North America Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 4: North America Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 5: U.S. Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 6: U.S. Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 7: U.S. Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 8: Canada Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 9: Canada Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 10: Canada Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 11: Europe Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 12: Europe Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 13: Europe Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 14: Germany Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 15: Germany Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 16: Germany Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 17: UK Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 18: UK Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 19: UK Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 20: France Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 21: France Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 22: France Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 23: Asia Pacific Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 24: Asia Pacific Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 25: Asia Pacific Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 26: Japan Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 27: Japan Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 28: Japan Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 29: India Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 30: India Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 31: India Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 32: China Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 33: China Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 34: China Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 35: China Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 36: China Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 37: China Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 38: Brazil Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 39: Brazil Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 40: Brazil Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 41: Mexico Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 42: Mexico Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 43: Mexico Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 44: MEA Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 45: MEA Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 46: MEA Biomarker market, by disease, 2013 - 2024 (USD Million)
  • TABLE 47: South Africa Biomarker market, by type, 2013 - 2024 (USD Million)
  • TABLE 48: South Africa Biomarker market, by application, 2013 - 2024 (USD Million)
  • TABLE 49: South Africa Biomarker market, by disease, 2013 - 2024 (USD Million)
Back to Top